Adicet Bio (ACET) gained 9.4% on Jul 8 and continued to gain another 2.6% during the after-market hours after the FDA granted Fast Track designation to its investigational candidate, ADI-270, for the potential treatment of patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC). ccRCC is a form of kidney cancer.The eligible patient population for the candidate includes ccRCC patients who have been treated with an immune checkpoint inhibitor and a vascular endothelial growth factor inhibito ...